DALLAS, July 17, 2014 /PRNewswire-iReach/ -- Among the five major pharmaceutical markets (5MM: Brazil, India, Mexico, Singapore and Thailand), Brazil and Mexico are projected to be the leading contributors to the dengue vaccine marketplace, as it expands rapidly from an estimated $70 million in 2015 to $400 million by 2020, at a Compound Annual Growth Rate (CAGR) of 42%, according to research and consulting firm.
The company's latest report "OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020" states that Brazil and Mexico will achieve a combined market share of over 98% across the 5MM in 2015, with respective sales of $45 million, equaling a 64% market share, and $24million (34%).
Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded flavivirus most commonly transmitted by the Aedes aegypti (A. aegypti) mosquito. Thought to be responsible for upwards of 100 million infections each year, DENV is the most prevalent arthropod-borne virus in the world. Individuals infected with DENV can present with a wide spectrum of symptoms, including fevers, retro-orbital pain, severe headache, muscle and joint pain, and rash. The severity of dengue fever ranges from asymptomatic cases, to classic dengue fever, and to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) that have a mortality rate of 5%–15%. Because there are no marketed dengue-specific vaccines or therapeutics, current treatment strategies are limited to supportive care for those already infected with the virus, and vector control to reduce DENV transmission.
Companies Profiles mention in this report are:
Key Questions Answered:
Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=292260 .
However, these shares will change dramatically by 2020, as Mexico will surge ahead to generate $217 million, a 54% market share, while Brazil's more modest growth will take it to $97 million (24%). Growth in Brazil will be stymied by the arrival of a domestically-produced, live-attenuated dengue vaccine, TV-003, which GlobalData expects to seize substantial market share from Big Pharma-manufactured vaccines due to its lower price per dose.
Researcher anticipates that the superior clinical and commercial positioning of live-attenuated dengue vaccines, led by Sanofi's CYD-TDV and Takeda's DENVax, will facilitate their market dominance, with sales of these products across the 5MM projected to reach $166 million, a 42% market share, and $148 million (37%), respectively, by 2020.
Request a sample copy @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=292260 .
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 After the Launch of the First Dengue Vaccine in 2015, the Market is Projected to Experience Rapid Growth Through 2020
2.2 From a Barren to Competitive Market: Vaccine Developers Will Need to Leverage Innovative R&D Strategies to Differentiate Themselves from Their Rivals
2.3 High Unmet Need for Safe and Efficacious Dengue Vaccines Expected to Facilitate Rapid Uptake of Pipeline Agents
2.4 Opportunities for Current and Future Players to Exploit Gaps in the Treatment Landscape Will Exist Throughout the Forecast Period and Beyond
2.5 Live-Attenuated Vaccines, Led by Sanofi's CYD-TDV, are Expected to Dominate the Dengue Vaccine Marketplace from 2015–2020
2.6 What Do Physicians and Specialists Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Dengue (2013–2023)
6 Current Surveillance, Prevention, and Control Measures
7 Unmet Needs Assessment and Opportunity Analysis
7.2 Unmet Needs Analysis
7.3 Opportunity Analysis
8 Research and Development Strategies
8.2 Technological Approaches to Vaccine Development
8.3 Partnerships, Acquisitions, and Licensing Agreements
8.4 Clinical Trial Design
9 Pipeline Assessment
9.2 Live-Attenuated Vaccines in Clinical Development
9.3 Other Vaccines in Clinical Development
9.4 Vaccines in Preclinical Development
10 Pipeline Valuation Analysis
11 Appendix 138
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Media Contact: Ritesh Tiwari, ReportsnReports, +18883915441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Copyright©2014 PR Newswire.
All rights reserved